
Aspen Neuroscience, Inc.
ASPEPricedAspen Neuroscience, Inc. · Nasdaq Global Select Market · Research source · S-1 · 2026-10-09 · Latest filing · 8-K · 2026-11-02 SEC ↗
Aspen’s preliminary IPO terms remain materially incomplete, with no price, size, proceeds or effective listing disclosed.
As of the October 9, 2026 S-1, Aspen proposed an IPO of common stock but left key pricing and share figures blank.
- Business and development direction
Aspen Neuroscience, Inc.
Current business Future development
Key risks
Risk 1
The company has limited operating history, no commercialization history and substantial accumulated losses, with going-concern doubt.
Risk 2
Failure or delay in sasineprocel development, regulatory approval or commercialization would materially harm the business because it is the lead product candidate.
Risk 3
Autologous manufacturing involves variability and the novel process may cause manufacturing failures, treatment delays or inconsistent quality.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Source-linked structured inputs are not yet available. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | Leerink Partners LLC | |||
| 2 | Piper Sandler & Co. | |||
| 3 | Stifel, Nicolaus & Company, Incorporated | |||
| 4 | UBS Securities LLC | |||
| 5 | Oppenheimer & Co. Inc. |
IPO CAPITAL QUALITY
Basis and evidence
S-1 · 2026-10-09
As of the October 9, 2026 S-1, Aspen proposed an IPO of common stock but left key pricing and share figures blank.
Offering structure
Source and calculation
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Pre-offer shares · Aspen Neuroscience, Inc. | 188,558,695 | — |
Basis and evidence ↗
As of June 30, 2026, after assumed preferred-stock conversion; offering basis
Reported inputs; each row retains its own source basis.
Share-count comparison
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source ↗IPO valuation scenario simulator
Source inputs required
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Source ↗Source and calculation ↗
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-10-09
Relationship filters
Select for details · Aspen Neuroscience, Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Entities affiliated with OrbiMed Private Investments VII, LPBeneficial shares | 25,586,039 | — | — | Number of Shares; Beneficially Owned |
| Entities affiliated with Gilead Sciences, Inc.Beneficial shares | 16,470,124 | — | — | Number of Shares; Beneficially Owned |
| Entities affiliated with Frazier Life Sciences X, L.P.Beneficial shares | 13,251,770 | — | — | Number of Shares; Beneficially Owned |
| Entities affiliated with Q Healthcare Holding LLCBeneficial shares | 13,176,099 | — | — | Number of Shares; Beneficially Owned |
| Entities affiliated with ARCH Venture Fund X, L.P.Beneficial shares | 23,930,336 | — | — | Number of Shares; Beneficially Owned |
| Entities affiliated with Abu Dhabi Investment AuthorityBeneficial shares | 12,816,358 | — | — | Number of Shares; Beneficially Owned |
| Entities affiliated with Medical Excellence Capital Partners, LPBeneficial shares | 10,658,060 | — | — | Number of Shares; Beneficially Owned |
| Damien McDevittBeneficial shares | 8,254,091 | — | — | Number of Shares; Beneficially Owned |
| Dalen MeeterBeneficial shares | 709,270 | — | — | Number of Shares; Beneficially Owned |
| Kim RaineriBeneficial shares | 1,114,583 | — | — | Number of Shares; Beneficially Owned |
| Faheem HasnainBeneficial shares | 1,249,982 | — | — | Number of Shares; Beneficially Owned |
| Thomas Daniel, M.D.Beneficial shares | 1,117,478 | — | — | Number of Shares; Beneficially Owned |
| Entities affiliated with OrbiMed Private Investments VII, LPBeneficial ownership | — | 13.1%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Entities affiliated with Gilead Sciences, Inc.Beneficial ownership | — | 8.4%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Entities affiliated with Frazier Life Sciences X, L.P.Beneficial ownership | — | 6.8%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Entities affiliated with Q Healthcare Holding LLCBeneficial ownership | — | 6.8%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Entities affiliated with ARCH Venture Fund X, L.P.Beneficial ownership | — | 12.3%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Entities affiliated with Abu Dhabi Investment AuthorityBeneficial ownership | — | 6.6%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Entities affiliated with Medical Excellence Capital Partners, LPBeneficial ownership | — | 5.5%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Damien McDevittBeneficial ownership | — | 4.2%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Andrew SpaventaBeneficial ownership | — | 1.9%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Peter A. Thompson, M.D.Beneficial ownership | — | 13.1%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| All executive officers and directors as a group (12 persons)Beneficial ownership | — | 21.2%Beneficial | — | Percentage of Shares Beneficially Owned; Before Offering |
| Caryn PetersonBeneficial shares | 410,473 | — | — | Number of Shares; Beneficially Owned |
| Andrew SpaventaBeneficial shares | 3,777,944 | — | — | Number of Shares; Beneficially Owned |
| Peter A. Thompson, M.D.Beneficial shares | 25,586,039 | — | — | Number of Shares; Beneficially Owned |
| All executive officers and directors as a group (12 persons)Beneficial shares | 42,852,151 | — | — | Number of Shares; Beneficially Owned |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller finding |
Source and calculation ↗
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with OrbiMed Private Investments VII, LP(1)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Gilead Sciences, Inc. (2)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Frazier Life Sciences X, L.P. (3)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Q Healthcare Holding LLC (4)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with ARCH Venture Fund X, L.P.(5)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Abu Dhabi Investment Authority (6)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Medical Excellence Capital Partners, LP (7)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Damien McDevitt (8)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Dalen Meeter (9)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Kim Raineri (10)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Faheem Hasnain (11)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Thomas Daniel, M.D.(12)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with OrbiMed Private Investments VII, LP(1)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Gilead Sciences, Inc. (2)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Frazier Life Sciences X, L.P. (3)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Q Healthcare Holding LLC (4)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with ARCH Venture Fund X, L.P.(5)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Abu Dhabi Investment Authority (6)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Medical Excellence Capital Partners, LP (7)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Damien McDevitt (8)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Andrew Spaventa (14)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Peter A. Thompson, M.D. (15)
Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition
Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: All executive officers and directors as a group (12 persons) (16)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Caryn Peterson (13)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Andrew Spaventa (14)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: Peter A. Thompson, M.D. (15)
Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Number of Shares; Beneficially Owned; source holder: All executive officers and directors as a group (12 persons) (16)
Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller finding
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Our directors and executive officers and substantially all of our securityholdersAfter date of this prospectus · Source conditions apply | 180 days |
| We, our officers, directors, and substantially all of our securityholders,After date of this prospectus · Source conditions apply | 180 days |
| We, our executive officers and directors and substantially all of our other existing security holdersAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
Our directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus &
SEC lock-up paragraph; source 1145445:1146332; SHA256 4c9c5a3d580c688c9836918f296b207506af64313e1abad0a00cccb778dce842 ↗We, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC.
SEC lock-up paragraph; source 3161450:3162937; SHA256 3aec14628e47d0be7eddd7b9151b83fc82272dbeb0e04e91cc554779dce5316d ↗We, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:
SEC lock-up paragraph; source 3275359:3276377; SHA256 3e965170460ce302569bc5d22176cf4329210d943f2f84f33dd880b7020d8f54 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- Our directors and executive officers and substantially all of our securityholdersOur directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus &
- We, our officers, directors, and substantially all of our securityholders,We, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC.
- We, our executive officers and directors and substantially all of our other existing security holdersWe, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:
| Holder / event | Term / date | Conditions |
|---|---|---|
| Our directors and executive officers and substantially all of our securityholders | 180 days | Our directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & |
| We, our officers, directors, and substantially all of our securityholders, | 180 days | We, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC. |
| We, our executive officers and directors and substantially all of our other existing security holders | 180 days | We, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: |
Basis and evidence
Our directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus &
SEC lock-up paragraph; source 1145445:1146332; SHA256 4c9c5a3d580c688c9836918f296b207506af64313e1abad0a00cccb778dce842 ↗We, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC.
SEC lock-up paragraph; source 3161450:3162937; SHA256 3aec14628e47d0be7eddd7b9151b83fc82272dbeb0e04e91cc554779dce5316d ↗We, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:
SEC lock-up paragraph; source 3275359:3276377; SHA256 3e965170460ce302569bc5d22176cf4329210d943f2f84f33dd880b7020d8f54 ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reportedOperating cash flow
$ · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss) | ($48,557,000) | ($62,056,000) |
| Operating cash flow | ($44,162,000) | ($52,847,000) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2025-12-31 | $82,097,000 |
| Cash and cash equivalents2024-12-31 | $15,221,000 |
| Current assets2025-12-31 | $112,386,000 |
| Current assets2024-12-31 | $59,590,000 |
| Total assets2025-12-31 | $143,663,000 |
| Total assets2024-12-31 | $90,211,000 |
| Current liabilities2025-12-31 | $14,263,000 |
| Current liabilities2024-12-31 | $14,038,000 |
| Total equity / (deficit)2025-12-31 | ($217,077,000) |
| Total equity / (deficit)2024-12-31 | ($157,727,000) |
| General and administrative expensesFY2025 | $17,472,000 |
| General and administrative expensesFY2024 | $17,865,000 |
| Cash and cash equivalents2026-06-30 · Unaudited | $21,287,000 |
| Current assets2026-06-30 · Unaudited | $74,595,000 |
| Total assets2026-06-30 · Unaudited | $110,275,000 |
| Current liabilities2026-06-30 · Unaudited | $16,352,000 |
| Total equity / (deficit)2026-06-30 · Unaudited | ($251,073,000) |
| General and administrative expenses6M ended 2026-06-30 · Unaudited | $9,764,000 |
| General and administrative expenses6M ended 2025-06-30 · Unaudited | $10,074,000 |
| Net income / (loss)6M ended 2026-06-30 · Unaudited | ($36,546,000) |
| Net income / (loss)6M ended 2025-06-30 · Unaudited | ($31,759,000) |
| Operating cash flow6M ended 2026-06-30 · Unaudited | ($34,505,000) |
| Operating cash flow6M ended 2025-06-30 · Unaudited | ($30,619,000) |
Basis and evidence
Financial quality and runway
Financial quality and runway
The latest supplied financial period is the unaudited six months ended June 30, 2026; the company reports losses, cash runway pressure and going-concern doubt.
EvidenceFinancial review 1Six-month 2026 operating expenses were $38.218 million and net loss was $36.546 million, in thousands in the table.
+
Six-month 2026 operating expenses were $38.218 million and net loss was $36.546 million, in thousands in the table.
EvidenceFinancial review 2Cash, cash equivalents and marketable securities were $72.4 million as of June 30, 2026, while accumulated deficit was $264.9 million.
+
Cash, cash equivalents and marketable securities were $72.4 million as of June 30, 2026, while accumulated deficit was $264.9 million.
EvidenceFinancial review 3Management concluded substantial doubt exists about continuing as a going concern because existing liquidity was not sufficient for the following 12 months from issuance of the unaudited financial statements.
+
Management concluded substantial doubt exists about continuing as a going concern because existing liquidity was not sufficient for the following 12 months from issuance of the unaudited financial statements.
EvidenceFinancial review 4Revenue and debt amounts are not supplied in the excerpts.
+
Revenue and debt amounts are not supplied in the excerpts.
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
No source-comparable material changes identified in this report.
S-10001193125-26-419104 ↗
Loading filing history…
The company has limited operating history, no commercialization history and substantial accumulated losses, with going-concern doubt.
Failure or delay in sasineprocel development, regulatory approval or commercialization would materially harm the business because it is the lead product candidate.
Autologous manufacturing involves variability and the novel process may cause manufacturing failures, treatment delays or inconsistent quality.
The open-label ASPIRO trial has no placebo or control cohort, limiting interpretation and predictive value of results.
- Evidence
- Risk Factors ↗